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MD Anderson
New MRI Techniques Pinpoint Brain
Tumors, Reveal Brain Fundions in Real Time
by Dawn Chalaire

szng a new,
faster, and more
powerful magnetic resonance
imaging (MRI)
scanner, researchers at The
University of Texas M . D.
Anderson Cancer Center
are delving deep into the
brain anatomy to see
where thoughts and
actions originate. Their
aim-to better characterize brain lesions and
develop more effective
but less neurologically
damaging treatments
for them.
The investigational neurovascular interactive (NV/ i )
scanner developed by GE
Medical Systems, with its faster
data acquisition and greater
processing power, is enabling
researchers to evaluate new

imaging techniques and proce
functional MR images in real time.
The
/ i is one of three high- p ed
MRI scanners acquired by the Department ofDiagno tic Radiology earli r
this year.
"The major ad antage of the
/ i
is that it allows us to assess the newer

imaging technique of diffu ion and
perfu ion, a well a timulated brain
function imaging, to better comprehend how the brain function ," aid
orman E. Leed , M.D., a profe or
in the Department of Diagrio tic
Radiology.
(Continued on next page)

Norman Leeds, M.D., Edward Jackson, Ph.D.,
X. Joe Zhou, Ph.D., and Krista McAlee, R.T. (left to
right), view images obtained with an investigational
magnetic resonance imagi,ng (MRI) scanner; the
NVIi, which enables researchers to evaluate

new imaging techniques and process
functional MR images
of the brain in
real time.

New MRI Techniques
( Continued from page 1)

Dr. Leeds and several physicists,
neuro-oncologists, neurosurgeons,
and neuropsychologists from M. D.
Anderson Cancer Center and Rice
University are designing and conducting studies using the new
scanner while working with the
manufacturer to evaluate and
refine the NV/ i's capabilities.
"This work is not simple. It requires a very knowledgeable team,"
Dr. Leeds said, "but it should allow
us to provide patient services that
most other centers can't."
Though researchers at M. D.
Anderson haye been able t9 do
functional MRI since 1997, the NV/ i
scanner greatly improves the image
quality they can achieve and allows
them to image, in real time, changes
in the brain as it activates functions
such as speech, memory, and movement. While functional areas of the
brain are generally found in the same
places in all humans, the specific sites
may vary slightly between individuals
and are often significantly affected
by the presence of tumors.
At M. D. Anderson, functional
MRI is being developed primarily
to help neurosurgeons plan resections of brain tumors. The images
provided by functional MRI techniques could not only reveal the
exact location of brain tumors but
also enable surgeons to precisely
locate adjacent functional areas so
as to allow surgery without damaging
critical structures.
Before functional MRI can be used
clinically, however, its accuracy must
be proved. To do this, the researchers
at M. D. Anderson are studying
functional task activation paradigms
designed to determine where motor
activity, expressive and receptive
speech, and memory are activated in
the brain. During a regularly scheduled MRI scan, patients are asked to
perform an activity such as tapping a
finger or silently generating words or
sentences while the NV/ i scanner
records changes in the area of the
brain that controls the activity in
real time.
''While the patient's in the scanner, we ask them to perform these
2 / MD Anderson OncoLog

tasks and then on a separate monitor
from the console where we normally
sit, we can actually see the buildup of
signal intensity in the areas of task
activation occurring in real time.
In the past when we did these functional studies we acquired the data,
then went away and processed it for
a couple of hours while crossing our
fingers in hopes that we got what we
needed," said EdwardJackson, Ph.D. ,
an assistant professor in the Department of Diagnostic Radiology.
To validate the functional MRI

"This work should allow
us to provide patient
services that most
other centers can't"
studies, control studies have been
done in 30 normal subjects. Also,
when the patients undergo surgery
for their tumors, neurosurgeons test
the accuracy of the functional MR
images by stimulating the brain to
be sure the corresponding electrical
activity in the brain occurs in the
same location that is indic'a ted on
the functional MR image.
"We're still at the stage of making
sure that what we see with the new
technique agrees with what we see
with established but more invasive
techniques," Dr.Jackson said.
Unlike positron emission tomography and surgical brain mapping,
functional MRI is completely noninvasive. Therefore, it could be
repeatedly used to assess the effects
of cancer treatments on brain
function, thus allowing oncologists
to more accurately weigh the benefits
and risks of surgical resection, radiation therapy, and chemotherapy.
Functional MRI could also determine
whether brain deficits are the result
of treatment or tumor recurrence.
Charles S. Cleeland, Ph.D., of the
Pain Research Group, is using
functional MRI to look at where
the brain processes painful stimuli
in order to understand how to target
those areas for pain relief.
The improved image quality and
faster acquisition rates of the NV/ i

scanner have also made it possible
to highlight changes in cerebral
blood volume and flow. With proper
manipulation of the data obtained,
such perfusion-weighted MRI scans
could distinguish necrosis caused by
radiation from tumor and possibly
determine tumor grade.
"The goal of radiation therapy
and chemotherapy is to control the
tumor by damaging it, which reduces
blood flow and results in some degree
of necrosis. Sometimes, however, it's
very difficult to separate tumor from
necrosis," Dr. Leeds said. "Perfusion
imaging should enable us to do so.
It should also permit us to evaluate
tumor activity and determine the
effects of treatment on the tumor
to better predict outcomes."
Dr. Leeds and his team are investigating the use of perfusion-weighted
MRI to determine the physical effects
on the brain of the cancer drug
interferon-alpha, which can cause
psychological changes in some
patients. Perfusion-weighted MRI is
also being used to look for changes
in blood volume and flow that
correspond to the clinical symptoms
of anemia and fatigue.
Moreover, in collaboration with
physicist X.Joe Zhou, Ph.D., the
NV/ i scanner is being used to evaluate another imaging technique that
could prove useful for delineating
areas of tumor, necrosis, and edema
within the brain. Unlike perfusionweighted MRI, diffusion-weighted
MRI does not require a contrast
agent. Instead, it relies on highspeed imaging techniques to measure the random motion of water
protons within the brain; areas of
restricted motion produce a bright
signal. The technique has been
used extensively to study areas of
restricted motion in the brains of
stroke patients. Its potential applications in patients with brain tumors
include better characterizing brain
lesions, identifying their extent,
and visualizing changes in the
brain's white matter tracts caused
by tumor growth. •
contact Dr: Leeds
at (713) 745-0562 or Dr.Jackson at
(713) 745-0559.

FOR MORE INFORMATION'

PROTOCOLS-1'--________
___,1
1

---4----

Liver Cancer
Clinical Trials
Clinical trials currently in progress at
The University of Texas M. D. Anderson
Cancer Center include the following
for patients with liver cancer or liver
metastases.
• A phase I dose-escalation trial of hepatic
artery infusion with an EF18-attenuated
adenovirus, ONYX-015, alone and in
combination with intravenous 5fluorouracil/leucovorin, into patients
with intrahepatic metastases from
gastrointestinal carcinoma (ID98-184).
Physician.· James L. Abbruzzese, M.D.
Study participants must have histologically or cytologically confirmed
colorectal, gastric, or pancreatic
carcinoma that has metastasized to the
liver. Their tumor must not be curable
with surgery but must be treatable with
perfusion via a hepatic artery catheter.
Participants must also be above 18
years old and have a life expectancy of
greater than 3 months and preserved
organ function. The participants will
return to M. D. Anderson up to 15 times
to receive an infusion of the adenovirus
ONYX-015 alone and combined with an
intravenous infusion of the drugs 5fluorouracil and leucovorin.
• A phase 11 trial of subcutaneous (SC)
recombinant human interferon alpha
(RIFNA2b) and continuous intravenous
(IV) 5-fluorouracil (5-FU) for the treatment
of hepatocellular carcinoma (HCC) (DM97040). Physician: Yehuda Z. Patt, M.D.
Patients with histologically proven
primary hepatocellular carcinoma
confined to the liver or that has metastasized are eligible for this study. Patients
who have never received treatment or

1
- - -

have received one higher priority
therapeutic regimen may participate.
Patients who have already received
RIFNA and 5-FU may not take part in
the study. Patients with tense ascites or
brain metastases or who are pregnant
or lactating also may not take part.
Patients will return to M. D. Anderson
on an outpatient basis to receive
infusions of 5-FU. Subcutaneous
injection of RIFNA2b, which will be done
three times a week, may be given by a
family physician. A family physician may
also perform weekly laboratory tests.
• Phase II trial of gemcitabine in the treatment of metastatic·or recurrent cholangiocarcinoma/gall bladder cancer (1098-360).
Physician: Yehuda Z. Patt, M.D.
To participate in this study, patients
must have biopsy-proven, measurable,
unresectable, locally advanced adenocarcinoma of the biliary ducts or gall
bladder. Patients also must be 18 years
of age or older and must not have
received prior chemotherapy for
metastatic disease. Patients who had
basal or squamous cell skin cancer or
cervical carcinoma in situ that has been
treated or cured or whose malignancy
has been in remission for more than
2 years may take part in the study. If
patients previously underwent surgery
that required general anesthesia and
enteral feedings, it must have been at
least 3 weeks prior to the beginning of
the study. Patients who are pregnant or
have a severe coexisting illness (i.e.,
poorly controlled diabetes mellitus,
oxygen-supplemented chronic obstructive pulmonary disease, unstable angina,
poorly controlled arrhythmia, infection)
may not participate. The chemotherapeutic drug gemcitabine will be given
to patients on an outpatient basis.

Correction to Compass
We regret that in the June 1999 issue of Compass, the last
sentence of the "Screening Recommendations" section contained
an error: We here reprint the entire "Screening Recommendations"
section. The last sentence contains the correction.

Screening Recommendations
Screening to detect early, treatable prostate cancers
is recommended. According to all of our experts, it is
important to help patients understand that current treatment approaches for localized prostate cancer are very

• Phase II study of radiofrequency
ablation of colorectal cancer liver
metastases combined with post-ablation
hepatic arterial infusion of floxuridine
alternating with 5-fluorouracil (ID98035). Physician: Lee Ellis, M.D.
To be eligible for this study, patients
must have histologically proven
colorectal cancer that has metastasized
to the liver. Patients who unsuccessfully
received systemic chemotherapy or
intra-arterial chemotherapy that did
not include 5-fluorouracil or fluoropyrimidine may participate. Patients with
clinical or radiographic evidence of
extrahepatic metastasis, liver tumors
greater than 4 cm in diameter, or more
than six liver tumors or who received
prior liver irradiation are ineligible. In
addition, patients with gross ascites,
evidence of cirrhosis, or active duodenal
or gastric ulcers may not participate.
Women who are pregnant or breastfeeding are also ineligible. Patients will
return to M. D. Anderson twice a month
to undergo radiofrequency ablation.
After ablation, patients will remain at
M. D. Anderson on an inpatient basis for
5 to 7 days. In addition to radiofrequency
ablation, patients will receive alternating
infusions of the chemotherapeutic drugs
floxuridine and 5-fluorouracil on an
outpatient basis. •
about these clinical
trials, physicians or patients may call the
M. D. Anderson Information Line. Those
within the United States should call (800)
392-1611; those in Houston or outside
the United States should call (713) 7926161. Visit theM. D. Anderson Cancer
Center clinical trials web site at http://
www.clinicaltrials.org for a broader listing
of treatment research protocols.
FOR MORE INFORMATION

favorable, based on survival data. Patients with earlystage disease have very good prognoses and a choice of
treatments with low complication rates, suggesting that
detecting early-stage disease is important.
According to Dr. Grossman, physicians at M. D.
Anderson endorse the approach of annual screening
(DRE and serum PSA) for men between the ages of 50
and 70. Where there is a family history of prostate cancer,
screening should begin at age 40. Screening is unnecessary
when there are other conditions limiting life expectancy
and no symptoms of prostate cancer. •
MD Anderson OncoLog / 3

Intra-Arterial Therapy Regains Spotlight

Aggressive Regional Therapies
Offer Some Promising Results for
Patients with Liver Tumors
by Dawn Chalaire

n treating liver tumors
with agents administered
by hepatic arterial infusion (HAI), Yehuda
Patt, M.D ., keeps a phrase
from H amlet in mind:
''Diseases desperate grown,
l7y desperate appliance are
relieved, or not at all. "

I

"Regional therapy such as HAI
is an attempt to extract the extra
mile from marginally effective
drugs," explained Dr. Patt, chief of
the Regional Therapy Service in
the Department of Gastrointestinal
Oncology and Digestive Diseases at
The University of Texas M. D. Anderson Cancer Center. "If we had drugs
that were concentration independent- that taken as a pill would
accomplish the same thing- nobody
would bother with HAI."
For years, HAI has been a source
of controversy among gastrointestinal
oncologists. It effectively delivers
high concentrations of cancer drugs
directly to liver tumors through the
hepatic artery while, in theory at
least, minimizing the drugs' systemic
effects on normal tissue. Yet, despite
evidence that HAI produces higher
local response rates than intravenous
chemotherapy, studies have failed to
convincingly show that HAI therapy
increases survival or improves quality
of life- until now.
At the American Society of Clinical Oncology (ASCO) meeting in
May, Nancy Kemeny et al. reported
significantly better survival after
HAI and systemic chemotherapy
than after systemic chemotherapy
alone in patients with colorectal
cancer following resection of liver
4 / MD Anderson OncoLog

metastases. Another study by the
Eastern Cooperative Oncology
Group and Southwest Oncology
Group showed that patients who
received a combination of HAI
and systemic chemotherapy after
hepatic resection of liver metastases
had fewer liver recurrences and a
longer time to recurrence compared
with patients treated with hepatic
resection alone.
"The ASCO meeting has stimulated us to reconsider the role of
intra-arterial therapy, probably in the
adjuvant setting, and to come up with
new trials that will address this role
and reduce some of the controversies, even within our own group,
over the best way to use this technology," said James Abbruzzese, M.D.,
chairman of the Department of
Gastrointestinal Medical Oncology
and Digestive Diseases.
The studies presented at the
ASCO meeting are significant, Dr.
Patt said, because it is impossible to
design a study to show the full extent
of HAI's survival benefits in patients
with liver metastases since patients
are enrolled into HAI therapy only
after frontline systemic therapy fails.
He predicted that these studies will
revive the use of HAI regimens.
"I definitely think HAI will be
used in adjuvant therapy after liver
resections or together with radiofrequency ablation, but I also believe
that we will see a surge in the use of
this therapy in patients with established liver metastases that have not
been resected," Dr. Patt said.
Currently, HAI is used at M. D.
Anderson to treat patients with
primary and metastatic liver tumors- most commonly hepatocellular carcinoma (HCC) and colon
cancer metastatic to the liver. HCC
accounts for about 250,000 deaths
worldwide each year but is relatively

uncommon in the United States,
although its incidence is rising.
Approximately 20% of colon cancer
deaths occur in patients with metastases confined to the liver. Becau se
recurrence is high and long-ter m
survival low for both diseases, HAI
is often used in clinical trials to
administer new agents or n ew
combinations of drugs.
"Our approach to treating
metastatic colon cancer, as well as
HCC, is to start with systemic therapies. If they work, that's fantastic
because then they work not only in
the liver but elsewhere also, and we
can resort to HAI in p atients who are
marginally responsive or n ot responsive to systemic or other drugs,"
Dr. Patt said.
At M. D. Anderson, the preferred
method of extended HAI is to place
a pump about 3 inches in diameter
half an inch beneath the skin of the
abdomen and connect it to a catheter implanted in the hepatic artery.
Drugs injected into the pump are
infused into the h epatic artery at a
constant rate. Although surgically
implanted, the pump still requires
a shorter hospital stay and creates
fewer co mplications than p ercutaneous therapy, which requires continuous hospitalization during infusion
and insertion of a n ew catheter
before each treatment. The pump
model used at M. D. Anderson for
several year s was recently discontinued, and now all patients who receive
HAI therapy for the first time must
enroll in a trial of an investigational
Medtronic pump led by Dr. Patt.
While most clinicians agree that
flaws in the methodologies of the
previous studies of HAI were at least
partly to blame for their lack of
definitive answers regarding patient
survival, it has been the risks associated with HAI that have fueled the

" ... we can resort to HAI in patients who are
marginally responsive or not responsive to
systemic or other drugs."
- Vehuda Patt, M.D.,
chief of the Regional Therapy Service, Department
of Gastrointestinal Oncology and Digestive Diseases
known gross disease in the liver,"
Dr. Ellis said.
Combining HAI with systemic
therapy is critical to treating liver
tumors, said Dr. Patt, who is conducting a pair of such clinical trials.
"Even though you can control
the disease in the liver for a certain
length of time , the disease will
change its natural course and eventually pop up outside the liver," he said.
In one such trial, Dr. Patt is
alternating HAI of floxuridine with
systemic i.v. CPT-11 in patients with
colon cancer metastatic to the liver
from gastrointestinal cancers.
and refractory to systemic fluorou"Right now, we think the best way
racil and leucovorin. In another trial,
to deliver the adenoviral compound
patients with HCC are being given
is locally or regionally. In a number
systemic i.v. platinum, interferon,
of studies, it has been delivered
Adriamycin (doxorubicin), and
fluorouracil (PIAF). If disease recurs
locally to other organs, and so a
logical extension is to try to deliver
or is confined to the liver only, the
it regionally, which is where the intra- same combination is given by HAI
arterial approach comes into play,"
to eliminate residual disease in the
Dr. Abbruzzese said. "This new
. liver and possibly make the patient
ONYX-015 study is not so much a
a candidate for resection. So far,
study of intra-arterial therapy as it is
according to Dr. Patt, one in four
a way to try to show the capabilities
patients has responded to systemic
of this particular adenovirus. It's still
PIAF, and the addition of HAI
premature to know if this is going to
administration has increased the
revolutionize intra-arterial therapy."
response rate to 46% and resulted in
Highlighting the trend toward
three complete histologic remissions
using HAI in adjuvant settings is a
among 15 registered patients.
phase II study led by Lee Ellis, M.D.,
"I must stress, though, that some
in the Department of Surgical
of these treatments, in hepatoma
Oncology. The study is combining
especially, may be lethal if you do
radiofrequency ablation of colorectal not choose your patients meticulously
cancer liver metastases with postor misapply treatment to poor
ablation HAI of floxuridine alternatcandidates," Dr. Patt said. "So, it's
ing with fluorouracil. Dr. Ellis said
extremely important to know who
that eligible patients must have no
you treat."
more than six liver lesions, all smaller
In carefully selected patients,
than 4 cm in diameter, and no extrahowever, aggressive HAI therapies
such as these offer promising results
hepatic metastases.
against diseases that can seldom be
"Giving a higher dose of chemorelieved by any other means. •
therapy directly to the liver and a
lower dose to the body makes us
FoR MORE INFORMATION, contact Dr. Patt
think HAI would be good to use in
at (713) 792-2828.
the adjuvant setting when there is no

Vehuda Patt, M.D.,

holds one of the
implantable
Medtronic pumps
used to administer
high concentrations
of chemotherapy
drugs, as well as
other agents such
as the adenovirus
ONYX-015, directly
to liver tumors
through the hepatic
artery.

.controversy. Attaching a catheter
to the hepatic artery, with or without
an implantable pump, can lead to a
variety of complications, especially
if the procedure is done by an
inexperienced surgeon. The high
concentrations of drugs delivered
in tra-arterially can also be harmful
to a patient's biliary tree.
Dr. Patt said that the toxicities
seen in some early trials of HAI have
led to more careful patient selection
and a wider selection of drugs and
drug combinations used with HAI.
"The advantage of using the
pump is that if the patient's tumor
stops responding to frontline HAI
therapy, we always have access to
the hepatic artery for studying new
agents," Dr. Patt said. "It gives us
that many more therapeutic and
investigational options."
One example of the investigational
options made possible by HAI is a
novel phase I study led by Dr.
Abbruzzese in which ONYX-015, an
adenovirus that targets tumor cells
lacking the p53 tumor suppressor
gene, is delivered via HAI. Stanford
University and the Mayo Clinic are also
participating in the multi-institutional
study of ONYX-015 with or without
intravenous fluorouracil and leucovorin in patients with liver metastases
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Upcoming Conferences Explore Many Topics
by Kimberly JT Herrick

he chart below lists
the conferences
sponsored lJy M. D.
Anderson Cancer
Center's Office of Continuing
Medical Education and
Conference Services from midSeptember 1999 to April 2000.

T

Continuing education credit
hours, including American Medical
Association/ Physicians Recognition
Award Category 1 (AMA/ PRA Cat. 1)
and other professional certifications,
are listed for those conferences for
which such certification has been
approved according to criteria of
the Accreditation Council for
Continuing Medical Education.
Additional and updated information about these and other confer-

ences and in-house educational events
at M. D. Anderson can be obtained
from the Conferences and Educational Events links on the M. D.
Anderson home page on the World
Wide Web (www.mdanderson.org) .
Contact M. D. Anderson Conference
Services by phone at (713) 792-2222,
facsimile at (713) 794-1724, or electronic mail (meetings@www.mdacc.
tmc.edu) for any additional information. •

Conferences Sponsored by The University of Texas M. D. Anderson Cancer Center
Date
Sept. 18, 1999
Sept. 24-25, 1999
Sept. 24-25, 1999
Oct. 2-5, 1999
Oct. 4-8, 1999

Conference
(Location)
Breast Cancer Update (Houston)
Living Fully with Cancer Conference (Houston)
Adolescent and Young Adult Issues in
Oncology (Houston)
21st Annual Pharmacy Symposium (Houston)

Oct. 19-21, 1999

Practical Training in lnterventional Radiology
(Houston)
Anderson's Alumni Conference, "Cancer CareUT M. D. Anderson Approach" (Houston)
New Drugs in GI Malignancies (Paris, France)

Oct. 21, 1999

Healthy Woman's Symposium (Houston)

Oct. 29-30, 1999

Issues in Prostate Cancer: A Conference for
Patients and Families (League City, TX)

Nov. 13, 1999

LMA Hands-on Workshop a Seminar for
Training, Education, and Research (Houston)

Nov. 16-22, 1999

Cancer in the Middle East: Current Status and
Future Collaborative Opportunities (Cairo and
Sharm El-Sheikh, Egypt)
Society for Neuro-Oncology Annual Meeting
(Scottsdale, Arizona)

Oct. 8-9, 1999

Nov. 18-21, 1999

Jan.9-12,2000

Feb. 6-9, 2000

Feb. 16-19,2000
Feb. 19-20, 2000
March 23-24, 2000
April 29, 2000

Cancer Research at the Millenium: 42nd Annual
Clinical Conference and 52nd Annual Symposium
on Fundamental Cancer Research (Houston)
Hawaii Endoscopy Conference, ''A Practical
Approach to Gastrointestinal, Pancreatobiliary,
and Hepatic Diseases" (Maui, Hawaii)
Radiation Oncology: RadOnc 2000 (Houston)
1st Annual Conference on Cancer-Related
Fatigue (Houston)
8th Annual Genitourinary Oncology
Conference (Houston)
Houston Society of Clinical Pathology (Houston)
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Chairpersons
(Contad)

Gabriel N. Hortobagyi, M.D.
Judy Gerner
Sima Jeha, M.D.
Sharon Bronson, M.S., and
William Dana, Pharm.D.
Contact Erlinda Alabastro at
713-792-2714.
Ralph Freedman, M.D.
Contact Jaffer Ajani, M.D., at
713-792-2828.
Diane Bodurka-Bevers, M.D.,
and Michelle Gershenson
Andrew von Eschenbach, M.D.,
Christopher Logothetis, M.D.,
and D. A Swanson, M.D.
David Ferson, M.D.
Contact Mary Ann Schneider
at 713-792-6911.
Contact Amr Soliman, M.D.,
Ph.D., at 713-792-4533.

Victor Levin, M.D.
Contact Jan Esenwein at
713-745-2344.
John Mendelsohn, M.D., and
Margaret Kripke, Ph.D.

Mid-September 1999
to April 2000

Continuing Education Credit
(Credit Hours)
AMA/PRA Category 1 (4.5)
AMA/PRA Category 1 (12.5

AMA/PRA Category 1 (14.5)

AMA/PRA Category 1 (6.5)

AMA/PRA Category 1 (25.5)

AMA/PRA Category 1 (22.5)

Isaac Raijman, M.D.

James D. Cox, M.D.
Charles Cleeland, Ph.D.
Christopher Logothetis, M.D.,
and Randall Millikan, M.D.
Elvia Silva, M.D.

2/19/2000-Nursing (Z4)
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Hormone Replacement Therapy: End
to Hot Flashes or Fuse for New Cancers?
eighing the benefits
and the risks of
hormone replacement therapy
(HR T) is an important
concern for middle-aged
women. On the one hand,
HRT's documented payoffs
include relief of menopausal
symptoms and prevention of
osteoporosis. On the other,
women who receive hormone
treatment may be increasing
their risks of breast and uterine
cancers.

Hormones and Menopause
Menopause, the absence of
menstrual periods for one year,
typically occurs in women between
the ages of 45 and 55. It may be
induced surgically by removal of the
uterus and ovaries. At menopause, a
woman 's ovaries stop producing the
fem ale sex hormone estrogen. This
lower level of estrogen then may
cause such menopausal symptoms as
hot flashes, night sweats, and vaginal
dryness. The lack of estrogen also
contributes to a woman's developing
osteoporosis or thinning of the
bones, which may lead to fractures.
The severity of menopausal
symptoms varies greatly among
women. About 80% of menopausal
women experience some symptoms,
but according to The Women's Fund
for Health Education and Research,
only 10% to 30% have complaints
serious enough to make them seek
help from a physician.

Payoffs of HRT
Hormone replacement therapy
consists of estrogen with or without
progesterone. These hormones may
be prescribed in the form of a pill,
patch, implant, or cream.

prescribed alone in women who have
not had a hysterectomy.
As protection against endometrial
cancer, M. D. Anderson physicians
advise that progesterone be added to
estrogen in either continuous or
cyclic fashion.

HRT and Breast Cancer

HRT has been shown to relieve
hot flashes, night sweats, insomnia,
and vaginal dryness in menopausal
women. It also helps prevent osteoporosis by promoting the absorption
of calcium, which slows down bone
loss.
Although some studies suggest
that HRT may reduce or postpone
a woman's risk of suffering a heart
attack or stroke, more research must
be done before this can be confirmed. This is true also for indications that HRT improves the verbal
memory skills of postmenopausal
women, decreases urinary incontinence and urinary tract infections,
and possibly reduces the risk of
developing colon cancer.

HRT and Endometrial Cancer
But hormone replacement
therapy also carries significant
health risks for some women. Estrogen used alone in women who still
have their uterus has been linked
to an increased risk of endometrial
cancer, the most common gynecologic malignancy. Estrogen overstimulates the growth of the lining of
the uterus, called the endometrium.
Adding the hormone progesterone to the estrogen replacement
decreases the risk of endometrial
cancer. The progesterone causes the
endometrium to slough off cells
every month. Estrogen now is rarely

Breast cancer is another concern
for women on HRT. Some studies
suggest an increased risk of breast
cancer among women who have used
high doses of estrogen or have used
estrogen for 10 years or more. The
American Cancer Society reports that
this risk applies only to current or
recent users. A woman's breast cancer
risk returns to that of the general
population within five years of
stopping estrogen replacement
therapy, the ACS says.
HRT generally is not recommended for women with known or
suspected cancer of the breast or
uterus.

HRT: Is it for You?
Whether or not to have hormone
replacement therapy is a decision a
woman should discuss with her
doctor. Issues to be considered are
the severity of the woman's menopausal symptoms, her family history

of cancers of the breast or uterus,
and her risk factors for heart disease
and osteoporosis. Only then can she
decide whether HRT is the right
choice for her. •
For more information, contact
your physician or contact the
M. D. Anderson Information Line:

({) (800) 392-1611 within
the United States, or
({) (713) 792-6161 outside
the United States.
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When it was first
developed, the
cancer antigen
(CA) 125 assay
provided the
first generally
available test for
monitoring the
courses of patients
with epithelial
ovarian cancer.
Over the last 15 years, we have learned a
great deal about its potential and limitations. More than 2,000 papers have been
published concerning laboratory and
clinical studies of CA 125. The original
CA 125 assay utilized the OC 125 antibody that recognizes the CA 125 epitope
on a high-molecular weight glycoprotein. Despite repeated attempts, the gene
encoding the peptide component has not
yet been cloned. Monoclonal ailtibodi~s
have been raised against other epitopes
expressed by this molecule, leading to
the development of the CA 125-II assay,
which exhibits less day-to-day variation.
Using either assay, elevated levels of CA
125 are detected in a number of benign
conditions. CA 125 can be expressed in
gynecologic and nongynecologic cancers,
but it is most consistently elevated in
epithelial ovarian cancer and is well
established as its best monitor.
The rate of decline in CA 125 during
primary chemotherapy has been an
important independent prognostic factor
in several multivariate analyses. Persistent
elevation of CA 125 at the time of
8 I MD Anderson OncoLog

second-look surgical surveillance
procedures predicts residual disease
with >95% specificity. Rising CA 125
values have preceded clinical detection of recurrent disease by at least
three months in most, but not all,
studies. Given the modest activity of
salvage chemotherapy, this information has not yet had an impact on
survival. Rising CA 125 values during
subsequent chemotherapy have been
associated with progressive disease in
more than 90% of cases. CA 125 levels
can also aid in distinguishing malignant from benign pelvic masses,
permitting effective triage of patients
for primary surgery.
Early detection of ovarian cancer
remains the most promising application of CA 125. An algorithm has been
developed that estimates the risk of
ovarian cancer based upon the level
and trend of CA 125 values. This early
detection strategy should provide
adequate specificity, but sensitivity
may not be optimal.
In the future, improved sensitivity
may be attained using multiple markers and neural network analysis. Most
serum tumor markers have been
proteins or carbohydrates, but such
lipid markers as lysophosphatidic
acid deserve evaluation. Genomic
and proteonomic technologies should
identify additional novel markers.
Adapted, with permission, from Bast RC, Xu Ff, Yu S,
Barnhill S, Zhang Z, Mills GB: International Journal

of Biological Markers 1998;13(4):179-87.
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